Friday, November 20, 2026
Translate
PrivacySubmit newsShare your story Newsletter Advertise
Breaking

Mesenchymal Stromal Cells

Dechra Targets 2027 for First Ready-to-Use Pet Cell Therapy via Gallant

Dechra Targets 2027 for First Ready-to-Use Pet Cell Therapy via Gallant

Dechra has completed its acquisition of biotechnology firm Gallant Pet to integrate off-the-shelf mesenchymal stromal cell therapies into its veterinary portfolio.

United StatesCompany press releases (PR Newswire)